Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey. (Q38248633)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

review article

3 references

14 September 2020

8 February 2021

Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

14 September 2020

1 reference

8 February 2021

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Gaëlle Mariaule

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

11 September 2014

3 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

14 September 2020

8 February 2021

3 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

14 September 2020

8 February 2021

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

14366-14382

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

16 February 2020

copyright license

2 references

14 September 2020

8 February 2021

0 references

Imatinib: a review of its use in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Mammalian cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Crystal structure of cyclin-dependent kinase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Principles of CDK regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Activation of the various cyclin/cdc2 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Cdc25: mechanisms of checkpoint inhibition and recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

The cdk-activating kinase (CAK): from yeast to mammals.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Cyclin-dependent kinase inhibitors: a survey of recent patent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Inhibitors of cyclin dependent kinases: useful targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

The CDK inhibitors in cancer research and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

CDK inhibitors in clinical development for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Cyclin dependent kinases in cancer: potential for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Cyclin-dependent kinase inhibitors as potential targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Cyclin-dependent kinase inhibitors closer to market launch?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Flavopiridol in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

ATP-noncompetitive CDK inhibitors for cancer therapy: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Cyclin-dependent kinase inhibitors move into Phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Blockbuster dreams for Pfizer's CDK inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Structure-activity relationship studies of flavopiridol analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Cyclin D as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

21 January 2018

Cyclin-Dependent Kinases

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Discovery of a Potential Allosteric Ligand Binding Site in CDK2

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914366

The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4

21 January 2018

1 reference

12 December 2020

[Nobel Prize in Medicine 2001: the universal key to cell division]

1 reference

12 December 2020

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

1 reference

12 December 2020

Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes

1 reference

12 December 2020

Terameprocol, a novel site-specific transcription inhibitor with anticancer activity.

1 reference

12 December 2020

Cyclin K goes with Cdk12 and Cdk13

1 reference

12 December 2020

Role of the p16 tumor suppressor gene in cancer

1 reference

12 December 2020

10.3390/MOLECULES190914366

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

release_amiwghuucjfjpg5s75fxyu3uje

16 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/amiwghuucjfjpg5s75fxyu3uje

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

PubMed publication ID

25215591

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215591%20AND%20SRC:MED&resulttype=core&format=json